AllSci News
NorthLinks Bio launches with USD 34m from RA Capital to advance intranasal antiviral HEX17
Boston-based NorthLinks Bio has launched with USD 34 million in financing from RA Capital Management to advance its intranasal prophylactic antiviral...
Trace Neuroscience launches first-in-class UNC13A restoration therapy into human ALS trials
South San Francisco-based Trace Neuroscience has dosed the first patients with TRCN-1023, an antisense oligonucleotide (ASO) targeting UNC13A protein...
EU approves AbbVie’s Maviret for acute hepatitis C, expanding use beyond chronic infection
The European Commission has approved Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection, making it the only therapy…
Arrowhead adds EU approval for Redemplo in FCS
Arrowhead Pharmaceuticals (Nasdaq: ARWR) has received European Commission marketing authorization for Redemplo (plozasiran) as an adjunct to diet to reduce triglyceride levels…
Osanni Bio secures USD 190m to scale platform across ophthalmology and cardiology programs
San Francisco-based Osanni Bio LLC has closed a USD 190 million Series B financing round to advance its multi-therapeutic platform, with active programs in...
Calico’s fosigotifator gains breakthrough designation for ultra-rare disease VWM
Calico Life Sciences, the San Francisco-based Alphabet-founded research organization focused on aging and age-related diseases, announced receipt of US FDA Breakthrough Therapy…
Definium raises USD 500m to push psychedelic-derived DT120 toward psychiatric disorder approval
New York-based Definium Therapeutics, Inc. (Nasdaq: DFTX) announced a proposed underwritten public offering of USD 500 million in common shares and, to...
Manufacturing-related FDA CRL delays Achieve’s cytisinicline approval timeline into 2027
Seattle and Vancouver-based Achieve Life Sciences, Inc. (Nasdaq: ACHV) disclosed that the US FDA issued a Complete Response Letter for the New…
Genetix expands gene therapy footprint into Middle East with SPIMACO manufacturing deal
Somerville, Massachusetts-based Genetix Biotherapeutics has struck an exclusive licensing and commercialization agreement with Saudi-based Saudi...
Gilead's Trodelvy becomes first ADC approved for first-line metastatic triple-negative breast cancer in EU
Gilead's sacituzumab govitecan (Trodelvy) has secured European Commission marketing authorization as a first-line monotherapy for metastatic triple-negative...
Susan G. Komen foundation issues USD 15.4m in grants for breast cancer research across 35 investigators
Susan G. Komen awards USD 15.4 million in breast cancer research grants
Pfizer's Seagen-acquired IB6 ADC fails primary survival test in advanced lung cancer
Pfizer (NYSE: PFE) reported that sigvotatug vedotin, an integrin beta-6 (IB6)-directed antibody-drug conjugate, failed to demonstrate a statistically...
BMS-partnered iza-bren becomes world’s first approved bispecific ADC with China NPC nod
China has issued a market approval for iza-bren (izalontamab brengitecan; BL-B01D1) as a treatment for nasopharyngeal carcinoma (NPC), marking the first regulatory…
Merck's tulisokibart becomes first anti-TL1A antibody to achieve Phase III remission in ulcerative colitis
Merck (NYSE: MRK) reported positive topline results from the Phase III ATLAS-UC Study 2, making tulisokibart (MK-7240) the first anti-TL1A monoclonal...
MoonLake raises USD 150m to commercialize sonelokimab ahead of hidradenitis suppurativa BLA filing
Switzerland-based MoonLake Immunotherapeutics (Nasdaq: MLTX) announced a proposed public offering of USD 150 million in Class A ordinary shares — with...
The AllSci Brief
Free, systematic R&D and deal news. Daily.